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ABSTRACT 
The ATP binding site located on the subunit B of DNA gyrase is an attractive target for the 
development of new antibacterial agents. In recent decades, several small-molecule inhibitor 
classes have been discovered but none has so far reached the market. We present here the 
discovery of a promising new series of N-phenylpyrrolamides with low nanomolar IC50 values 
against DNA gyrase, and submicromolar IC50 values against topoisomerase IV from Escherichia 
coli and Staphylococcus aureus. The most potent compound in the series has an IC50 value of 13 
nM against E. coli gyrase. Minimum inhibitory concentrations (MICs) against Gram-positive 
bacteria are in the low micromolar range. The oxadiazolone derivative 11a, with an IC50 value of 
85 nM against E. coli DNA gyrase displays the most potent antibacterial activity, with MIC 
values of 1.56 µM against Enterococcus faecalis, and 3.13 µM against wild type S. aureus, 
methicillin-resistant S. aureus (MRSA) and vancomycin-resistant Enterococcus (VRE). The 
activity against wild type E. coli in the presence of efflux pump inhibitor phenylalanine-arginine 
β-naphthylamide (PAβN) is 4.6 µM. 
 
KEYWORDS: antibacterial; DNA gyrase; GyrB; inhibitor; N-phenylpyrrolamide; ParE; 
topoisomerase IV 
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ABBREVIATIONS 
ATCC, American type culture collection; ATR, attenuated total reflectance; CDI, 1,1'-
carbonyldiimidazole; CFU, colony-forming unit; CLSI, Clinical and Laboratory Standards 
Institute; DIAD, diisopropyl azodicarboxylate; DTT, dithiothreitol; FBS, fetal bovine serum; 
GyrA, DNA gyrase A; GyrB, DNA gyrase B; HepG2, human hepatocellular carcinoma cell line; 
HUVEC, human umbilical vein endothelial cells; MH, Mueller Hinton; MRSA, methicillin-
resistant Staphylococcus aureus; MTS, 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium; NMM, N-methylmorpholine; ParC, 
topoisomerase IV subunit A; ParE, topoisomerase IV subunit B; PAβN, phenylalanine-arginine 
β-naphthylamide; RA, residual activity; TBTU, N,N,N′,N′-tetramethyl-O-(benzotriazol-1-
yl)uronium tetrafluoroborate; topo IV, topoisomerase IV; VRE, vancomycin-resistant 
Enterococci. 
 
INTRODUCTION 
The discovery of antibacterials is considered to be one of the greatest medical achievements of all 
time. However, since the 1960s only a small number of new-class antibacterial agents have 
reached clinical practice while, on the other hand, the number of multi-drug resistant (MDR) 
bacteria is rising [1, 2]. Nowadays, we are increasingly faced with life-threatening infections due 
to resistant Gram-positive and Gram-negative pathogens that belong to the “ESKAPE” group 
(Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter 
baumannii, Pseudomonas aeruginosa, and Enterobacter species). Thus, the ESKAPE pathogens 
were included by the World Health Organisation in the »WHO priority pathogens list for R&D of 
new antibiotics« [3, 4]. 
DNA gyrase (gyrase) is a member of bacterial type IIA topoisomerase enzymes [5] that control 
the topology of DNA during processes of transcription, replication and recombination by 
introducing transient breaks to both DNA strands [6, 7]. DNA gyrase helps relieve torsional 
tension by introducing negative supercoils to the DNA molecule during replication. It is a 
heterotetrameric protein composed of two GyrA subunits where the DNA cleavage site is located, 
and two GyrB subunits that provide the energy necessary for the catalytic function of the enzyme 
through ATP hydrolysis [6, 8, 9]. The four subunits form a functional tetramer A2B2. The other 
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member of bacterial type IIA topoisomerases, topoisomerase IV (topo IV), is composed of two 
ParC and two ParE subunits that possess homologous structures to GyA and GyrB subunits of 
DNA gyrase. The main function of topo IV is decatenation of two daughter chromosomal DNA 
molecules after replication [8]. The structural and functional similarities of the two enzymes 
indicate that there is a possibility of designing inhibitors that target active sites of both gyrase and 
topo IV. This could reduce the capacity of bacteria to develop target-based drug resistance, since 
the probability of concurrent mutations on both targets is low [10]. Drugs targeting bacterial type 
IIA topoisomerases act by two main mechanisms, either by stabilizing the complex between a 
DNA molecule and the ParC/GyrA active site of the enzyme (e.g. quinolones), or by inhibiting 
the ATPase activity of the ParE/GyrB subunit (e.g. aminocoumarin class of inhibitors) [5, 6]. 
Novobiocin, a representative of the natural aminocoumarins, is the only ATP-competitive 
inhibitor to have been used in the clinic but it has been withdrawn due to its toxicity and low 
effectiveness [11]. Studies of many co-crystal structures of ParE and GyrB subunits with small 
ligands and fragment-based design campaigns have led to several new classes of GyrB/ParE 
inhibitors being discovered (Figure 1) [8, 10]. However, none of them have advanced beyond 
phase I clinical trials, and most are only active against Gram-positive bacteria [10-12].  
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Figure 1. Representative DNA gyrase B inhibitors: benzothiazole A [13], pyrrolopyrimidine B 
[14], indazole C [15], pyrrolamide D [16], pyrimidoindole E [17], azaindole urea F [18], and their 
IC50 or Ki, and MIC values. 
 
RESULTS AND DISCUSSION 
Design. The design of the presented set of compounds was based on our previous N-
phenylpyrrolamide inhibitors which had low nanomolar inhibitory activities against E. coli 
gyrase (IC50 < 100 nM). An example is compound D (Figure 2a) [16]. The aim was to improve 
the GyrB/ParE binding affinity of compounds and their antibacterial activity by structural 
modifications, resulting in type I (Schemes 1-3) and type II (Scheme 4) compounds (Figure 2b). 
For easier discussion, we have divided the structures into three parts: Part A, Part B and Part C 
(Figure 2a). 
To Part A, we introduced either a 4,5-dibromo-1H-pyrrole or a 3,4-dichloro-5-methyl-1H-pyrrole 
group. The pyrrole NH and pyrrolamide C=O groups are important hydrogen bond donor and 
acceptor groups that interact with Asp73 (E. coli numbering) and with a conserved water 
molecule (Figure 2c) in the GyrB binding site. Halogen atoms on the pyrrole moiety lower the 
pKa of the NH group and thus strengthen the formed H-bond. Chlorine and bromine atoms also 
increase the lipophilicity of the pyrrole moiety and thus increase hydrophobic interactions with 
the amino acid residues in the hydrophobic pocket of the enzyme (Val43, Ala47, Val71, Val167). 
On the Part B benzene ring, compound D contains a lipophilic isopropoxy substituent that can 
form hydrophobic interactions with residues Ile78 and Ile94 in the lipophilic floor of the enzyme. 
Since these interactions were found to be favourable for the binding affinity, in some type I 
compounds (7a-f, 8a-f, 10a, 11a and 15a-b) the isopropoxy group on the 3-position of the 
benzene ring was retained. To other type I compounds (9a-e and 12) we introduced a 2-
aminoethoxy substituent at this position, with the aim of improving the solubility of the 
compounds and/or broadening their antibacterial spectrum. Recently, the presence of an amino 
group, especially a primary amino group, was found to contribute to the ability of compounds to 
accumulate in Gram-negative E. coli [19]. With the type II compounds, we further explored the 
lipophilic floor of the enzyme by changing the position of substituents on the benzene ring from 
position 3- to 2-position. Similarly as in some type I compounds, in some type II compounds 
(22c-d and 23c-d) we introduced the isopropoxy substituent to the 2-position of the benzene ring. 
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In other type II compounds we introduced a sterically larger benzyloxy substituent (compounds 
22a and 23a) or a basic 2-(dimethylamino)ethoxy substituent (compounds 22b and 23b), with the 
aim of enabling additional interactions with the enzyme and improving the water solubility of the 
compounds. 
To Part C of type I compounds, groups that are able to form either ionic interactions with Arg136 
side chain or π-stacking interactions with the Glu50-Arg76 salt bridge were attached. The 
influence of different α-amino acids attached to Part C was studied, aiming to determine how the 
stereochemistry and the size of the amino acid side chain affect the binding affinity. Thus, 
glycine, L- and D-alanine, L-valine, and L-phenylalanine derivatives were prepared. The activities 
of these derivatives, in the form of methyl esters, free carboxylic acids, and hydrazides, were 
compared. Additionally, three compounds (11a, 11b and 12), each with a 1,3,4-oxadiazol-2-one 
ring as bioisosteric replacement for the carboxylic acid functionality, were prepared to reduce the 
acidity and polarity and thus improve bacterial cell membrane penetration of the compounds [20, 
21]. Furthermore, two compounds, each with a pyridine containing substituent in Part C, pyridin-
2-ylmethanamine (n = 1, compound 15a) and 2-(pyridin-2-yl)ethan-1-amine (n = 2, compound 
15b) were synthesized, and the optimal length for the activity determined. The pyridine moiety 
was intended to enable π-stacking interactions with the Glu50-Arg76 salt bridge. 
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Figure 2. a) A representative N-phenylpyrrolamide D and its inhibitory activities on DNA gyrase 
and topoisomerase IV [16]; b) Structures of type I and type II N-phenylpyrrolamide inhibitors; c) 
Docking binding mode of inhibitor D coloured according to the atom chemical type (C, yellow; 
N, blue; O, red; Cl, green) in the ATP binding site of E. coli GyrB (in cyan, PDB code: 4DUH 
[22]). The water molecule is presented as a red sphere. 
 
Chemistry. The synthesis of type I compounds (8a-i, 9a-e, 11a-b, 12, 15a-b) is presented in 
Schemes 1 to 3. 3-Hydroxy-4-nitrobenzoic acid (1) was reacted with thionyl chloride in methanol 
to give methyl ester 2, which was converted to 3a in a Mitsunobu reaction using isopropanol, and 
to 3b in the presence of potassium carbonate using tert-butyl (2-chloroethyl)carbamate as an 
alkylating agent. Compounds 3a-b were hydrolysed with 1 M sodium hydroxide to give 
carboxylic acids 4a-b, which were coupled with different amino acid methyl esters using TBTU 
(N,N,N',N'-tetramethyl-O-(benzotriazol-1-yl)uronium tetrafluoroborate) in order to prepare 
amides 5a-g. The nitro groups of 5a-g were reduced by catalytic hydrogenation to give amines 
6a-g. Compounds 6a-g were then coupled with 4,5-dibromopyrrole-2-carboxylic acid (to give 7a-
c and 7g-h) or with 3,4-dichloro-5-methylpyrrole-2-carboxylic acid to give 7d-f and 7i in a two-
step reaction. Oxalyl chloride was used to form pyrrole-2-carboxylic acid chloride in the first step 
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followed by its aminolysis in pyridine in the second step. Products 8a-i were prepared by alkaline 
hydrolysis of 7a-i. Removal, by acidolysis, of the Boc protecting group from compounds 7h-i and 
8g-i led to the final compounds 9a-e. Compounds 7e and 7i were additionally reacted with 
hydrazine monohydrate under reflux to prepare hydrazides 10a-b. These were converted to 11a-b 
using 1,1'-carbonyldiimidazole (CDI) at 100 °C. The Boc protecting group was removed from 
11b to yield the target compound 12. 
To prepare products 15a-b, 4a was first coupled with pyridin-2-ylmethanamine (to prepare 
13a) or 2-(pyridin-2-yl)ethan-1-amine (to prepare 13b) using TBTU. Reducing the nitro groups 
of 13a-b by catalytic hydrogenation led to compounds 14a-b. The final products 15a-b were 
prepared by coupling amines 14a-b with 4,5-dibromopyrrole-2-carboxylic acid. 
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Scheme 1. Reagents and conditions: (a) thionyl chloride, MeOH, 0 °C → rt, 15 h; (b) 
isopropanol, triphenylphosphine, diisopropyl azodicarboxylate, THF, rt, 15 h (for the synthesis of 
3a), tert-butyl (2-chloroethyl)carbamate, K2CO3, KI, DMF, rt → 60 °C, 15 h (for the synthesis of 
3b); (c) 1 M NaOH, MeOH, rt, 15 h; (d) corresponding amino acid methyl ester hydrochloride, 
TBTU, NMM, CH2Cl2, rt, 15 h; (e) H2, Pd-C, MeOH, rt, 2-4 h; (f) corresponding pyrrole 
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carboxylic acid, oxalyl chloride, CH2Cl2, rt, 15 h, then ii) 6a-g, pyridine, CH2Cl2, rt, 15 h; (g) 1 
M NaOH, MeOH/THF, rt, 15 h (for the synthesis of 8a-e and 8g-i) or 1 M LiOH, MeOH/THF, rt, 
4 h (for the synthesis of 8f); (h) 4 M HCl in 1,4-dioxane, THF, rt, 2 h. 
 
 
Scheme 2. Reagents and conditions: (a) hydrazine monohydrate, MeOH/THF, 65 °C, 15 h (for 
the synthesis of 10a) or 4 d (for the synthesis of 10b); (b) CDI, 1,4-dioxane/DMF, 100 °C, 15 h; 
(c) 4 M HCl in 1,4-dioxane, THF, rt, 5 h. 
 
 
Scheme 3. Reagents and conditions: (a) pyridin-2-ylmethanamine (for the synthesis of 13a) or 2-
(pyridin-2-yl)ethan-1-amine (for the synthesis of 13b), TBTU, NMM, CH2Cl2, rt, 15 h; (b) H2, 
Pd-C, MeOH, rt, 5 h; (c) 4,5-dibromopyrrole-2-carboxylic acid, oxalyl chloride, CH2Cl2, rt, 15 h, 
then ii) 14a-b, pyridine, CH2Cl2, rt, 15 h. 
 
The synthesis of type II compounds (23a-d) is outlined in Scheme 4. 2-Hydroxy-4-nitrobenzoic 
acid (16) was converted to its methyl ester 17 using thionyl chloride in methanol. Compounds 
18a-b were prepared by reacting 17 with benzyl bromide or β-dimethyl-aminoethylchloride 
hydrochloride using potassium carbonate, while 18c was synthesized under Mitsunobu 
conditions, using isopropyl alcohol. Alkaline hydrolysis of methyl esters 18a-c led to carboxylic 
acids 19a-c, which were coupled with glycine methyl ester hydrochloride, using TBTU, to give 
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20a-c. The amines 21a-c obtained after reduction of nitro groups of 20a-c were coupled with 
either 4,5-dibromopyrrole-2-carboxylic acid to give 22a-c, or 3,4-dichloro-5-methylpyrrole-2-
carboxylic acid to give 22d. Finally, methyl esters of 22a-d were hydrolysed with 1 M sodium 
hydroxide to give target compounds 23a-d. 
 
 
Scheme 4. Reagents and conditions: (a) thionyl chloride, MeOH, 0 °C → rt, 15 h; (b) K2CO3, 
benzyl bromide, CH3CN, 60 °C, 15 h (for the synthesis of 18a), β-dimethyl-aminoethylchloride 
hydrochloride, K2CO3, THF, 60 °C, 72 h (for the synthesis of 18b), isopropanol, 
triphenylphospine, DIAD, THF, rt, 15 h (for the synthesis of 18c); (c) 1 M NaOH, MeOH, rt, 15 
h; (d) glycine methyl ester hydrochloride, TBTU, NMM, CH2Cl2, rt, 15 h; (e) SnCl2, 
EtOAc/MeOH, 55 °C, 15 h (for the synthesis of 21a), H2, Pd-C, MeOH, rt, 3 h, (for the synthesis 
of 21b-c); (f) the corresponding pyrrole carboxylic acid, oxalyl chloride, CH2Cl2, rt, 15 h, then ii) 
21a-c, pyridine, CH2Cl2, rt, 15 h; (g) 1 M NaOH, MeOH/THF, rt, 15 h. 
 
Inhibitory Activities against DNA Gyrase and Topoisomerase IV. All final compounds 
were evaluated for their inhibitory activity against E. coli DNA gyrase in a supercoiling assay. 
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Results are presented as residual activities (RAs) of the enzyme at 1 µM of compounds or as IC50 
values for compounds with RA < 50% (Tables 1-2). Compounds with submicromolar IC50 values 
were evaluated against S. aureus DNA gyrase, and E. coli and S. aureus topoisomerase IV (Table 
3). To determine the possible binding modes of compounds, molecular docking of all tested 
compounds to the E. coli GyrB binding site was performed, using GOLD software [23]. 
Compounds 8e, 8f, 9b, 9e, 11a, 12, 23a and 23d showed inhibitory activities stronger than that 
of novobiocin (IC50 = 170 nM) against E. coli DNA gyrase, with low nanomolar inhibitory values 
(IC50 ≤ 91 nM). Seven of the eight most active compounds contained the 3,4-dichloro-5-methyl-
1H-pyrrole moiety in Part A of the molecules, which thus proved to be more suitable than the 
4,5-dibromo-1H-pyrrole moiety. The reason for this is probably the slightly smaller size of the 
chloro and methyl substituents than of the bromo substituents which bind to the hydrophobic 
pocket of the enzyme more strongly [16]. Compounds with free carboxylic acid groups in the 
eastern part of the molecules showed more potent activities than did their methyl ester analogues. 
For example, methyl ester 7f was almost inactive at 1 µM concentration (RA = 87%), while its 
carboxylic acid derivative 8f had an IC50 value of 41 nM and was among the most potent 
compounds of the series. Free carboxylic acids are able to form ionic interactions and/or 
hydrogen bonds with the Arg136 side chain in the binding site of the enzyme, while esters can 
only form hydrogen bonds, thus resulting in their weaker activity. A similar trend can be 
observed for other carboxylic acid – methyl ester pairs presented in Tables 1 and 2. The only 
methyl ester derivative with activity in the low nanomolar range was compound 9b, with an IC50 
value of 34 nM. Further, in some type I compounds (compounds 7e and 7i), methyl ester groups 
were converted to hydrazides (compounds 10a and 10b), which were then further converted to 
oxadiazolone rings (compounds 11a-b and 12). The activities of hydrazides (10a, IC50 = 280 nM) 
were weaker than those of the corresponding carboxylic acids (8e, IC50 = 38 nM) or 
oxadiazolones (11a, IC50 = 85 nM), probably because they cannot form ionic interactions with 
Arg136. On the other hand, both compound 8e with a carboxylic acid group (IC50 = 38 nM) and 
its oxadiazolone containing analogue 11a (IC50 = 85 nM) inhibited the enzyme in the low 
nanomolar range, although compound 8e was approximately two-fold more potent. A different 
result was observed when oxadiazolone 12 (IC50 = 13 nM) was compared with its carboxylic acid 
analogue 9e (IC50 = 28 nM), where the former was more potent. The only compound containing 
an oxadiazolone ring that did not show low nanomolar potency was 11b, with an IC50 value of 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
1.6 µM, probably because it contains a side chain with the sterically larger tert-butyl carbamate 
group. 
As reported recently [16], lipophilic substituents at the 3-position of the Part B benzene ring 
(e.g. methoxy, isopropoxy and benzyloxy substituents) form favourable interactions with the 
hydrophobic floor of the enzyme. In type I compounds, three different substituents have thus 
been introduced at this position: isopropoxy, 2-aminoethoxy and N-Boc-2-aminoethoxy 
substituents. Analogues with either an isopropoxy (8e, IC50 = 38 nM) or a 2-aminoethoxy 
substituent (9e, IC50 = 28 nM) had greater activity than analogues with an N-Boc-2-aminoethoxy 
substituent (8i, IC50 = 590 nM), probably because the tert-butyl carbamate group is too large to fit 
into the binding site of the enzyme. When compounds with isopropoxy and 2-aminoethoxy 
substituents were compared, the latter were generally more potent, as seen by comparing the 
isopropoxy derivatives 8d (RA = 91% at 1 µM) and 7e (RA = 66% at 1 µM) with their 2-
aminoethoxy counterparts 9d (IC50 = 370 nM) and 9b (IC50 = 34 nM). Based on the docking 
experiments, it was predicted that the amino group of the 2-aminoethoxy substituent could form 
an H-bond with Ala100 that is part of the flexible loop formed by Gly97-Ser108 (compound 9e, 
Figure 3), thus increasing the inhibitory potency. Similarly, in the crystal structure of a bithiazole 
inhibitor in complex with E. coli GyrB reported by Brvar et al. (PDB code: 4DUH [22]), a 
hydrogen bond was seen with Gly101 that is also a part of this loop. These interactions could 
stabilize the loop, reduce its flexibility and lead to stronger binding of the inhibitor. 
 
Figure 3. The GOLD-predicted binding pose of inhibitor 9e (in orange sticks) in the E. coli GyrB 
ATP-binding site (PDB entry: 4DUH [22], in grey). Hydrogen bonds are presented as green 
dashed lines. The water molecule is shown as a red sphere. The figure was prepared with PyMOL 
[24]. 
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To Part C of the type I compounds, we attached various amino acids: glycine, L- and D-alanine, 
L-valine and L-phenylalanine. Additionally, two compounds (15a and 15b) were prepared with 
side chains containing a pyridine ring bound through either a methylene or an ethylene linker to 
the central benzamide core. Compounds with alanine side chains displayed the strongest 
inhibitory activity of the series while L-phenylalanine containing compounds were the weakest. 
For example, L-alanine analogue 8c exhibited an IC50 value of 370 nM, while its L-phenylalanine 
containing counterpart 8b was inactive at 1 µM concentration (RA = 100%). From these results it 
can be concluded that the benzyl group of the L-Phe side chain does not form favourable 
hydrophobic or π-π interactions with the enzyme. Furthermore, the size of the L-Phe group may 
force the molecule to take up an unfavourable conformation. Because of its size and flexibility, 
the benzyl group might be oriented out of the binding site towards the solvent, as was predicted 
with molecular docking of compound 8b into the E. coli GyrB ATP-binding site (Figure 1Sa, 
Supporting information). There were no marked differences in the activities of L-alanine 
(compound 8e, IC50 = 38 nM) or D-alanine containing compounds (compound 8f, IC50 = 41 nM). 
Compounds 15a and 15b, with pyridine containing groups, were not active against E. coli gyrase 
(RA = 100% or 87%). Even though the interaction between the pyridine nitrogen of compound 
15a and Arg76 was predicted by molecular docking, this side chain is probably too flexible to 
form a stable contact with Arg76 (Figure 1Sb, Supporting information). 
To further explore the binding site, type II compounds with substituents at the 2-position of the 
Part B benzene ring were prepared. Compounds with isopropoxy, benzyloxy and 2-
dimethylaminoethoxy groups at this position were evaluated. As in type I compounds, only 
compounds with free carboxylic acid groups in the eastern part of the molecules showed 
nanomolar enzymatic inhibition. Compound 23b, with a 2-dimethylaminoethoxy substituent (RA 
= 82% at 1 µM), showed the weakest activity of the series. The benzyloxy analogue 23a (IC50 = 
88 nM) was the most active type II compound, being 4-fold more active than its isopropoxy 
analogue 23c (IC50 = 400 nM), indicating that it can form stronger hydrophobic interactions with 
the enzyme. A second very potent compound in the type II series was compound 23d (IC50 = 91 
nM) with an isopropoxy substituent on the benzene ring and a 3,4-dichloro-5-methylpyrrole 
group attached as Part A. 
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In general, the activities on DNA gyrase from S. aureus and on topo IV from E. coli and S. 
aureus were weaker than those on E. coli gyrase, but compounds 8e, 9e and 12 that were among 
the most potent inhibitors of E. coli gyrase also displayed promising results on these three 
enzymes (Table 3). Compounds 8e, 9e and 12 had IC50 values in the submicromolar range (< 1 
µM) against E. coli topo IV, which is much lower than that for novobiocin (IC50 = 11 µM). 
Compound 8e, with an isopropoxy substituent, and compound 9e, with aminoethoxy substituent 
on the 3-position of the benzene ring, additionally showed nanomolar IC50 values (93 nM and 
110 nM, respectively) against S. aureus gyrase. Compound 8e displayed the most balanced 
activities against all four tested enzymes, with a low IC50 of 280 nM also against S. aureus topo 
IV (IC50 of novobiocin is 27 µM) and thus appears to be a promising dual-target inhibitor. 
Interestingly, compound 8f, a D-alanine analogue of 8e, that showed an activity comparable to 
that of 8e on DNA gyrase from E. coli, did not display the same potency on the other three 
enzymes. Since there are certain structural differences between the enzymes, the stereochemistry 
could be more important in the latter. A difference between 9e and its methyl ester analogue 9b 
was also observed, with weaker activities of the latter on all enzymes. These results correlate well 
with those for E. coli gyrase, leading to the assumption that an acidic functional group is also 
important for the binding to S. aureus gyrase and to topo IV from E. coli and S. aureus. Similarly, 
the carboxylic acid analogue 8e displayed stronger activity than either the corresponding 
hydrazide 10a or the oxadiazolone 11a on these enzymes. Furthermore, the activity of the 3,4-
dichloro-5-methyl-pyrrolamides (8e, 8f, 8i, 9b, 9e, 10a, 11a, 12 and 23d) was stronger than that 
of the 4,5-dibromopyrrolamides (8c, 9d, 23a and 23c). The reason probably lies in the smaller 
size of the binding pockets of S. aureus DNA gyrase and of topo IV that results from differences 
in certain amino acid residues in the ATP binding site [25, 26]. 3,4-Dichloro-5-
methylpyrrolamides with smaller groups on the pyrrole ring bind more effectively to the enzyme. 
 
Table 1. Inhibitory activity of type I compounds 7a-i, 8a-i, 9a-e, 10a-b, 11a-b, 12 and 15a-b 
against DNA gyrase from E. coli. 
 
Compd. R1 R2 R3 R4 * IC50 (nM)a or RA (%)b 
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E. coli gyrase 
7a 4,5-diBr iPr iPr COOMe
 
L 94% 
7b 4,5-diBr iPr Bn COOMe L 100% 
7c 4,5-diBr iPr CH3 COOMe L 93% 
7d 3,4-diCl-5-Me iPr Bn COOMe
 
L 100% 
7e 3,4-diCl-5-Me iPr CH3 COOMe L 66% 
7f 3,4-diCl-5-Me iPr CH3 COOMe D 87% 
7g 4,5-diBr CH2CH2NHBoc H COOMe / 53% 
7h 4,5-diBr CH2CH2NHBoc Bn COOMe L 100% 
7i 3,4-diCl-5-Me CH2CH2NHBoc CH3 COOMe L 100% 
8a 4,5-diBr iPr iPr COOH L 70% 
8b 4,5-diBr iPr Bn COOH L 100% 
8c 4,5-diBr iPr CH3 COOH L 370 ± 160 nM 
8d 3,4-diCl-5-Me iPr Bn COOH L 91% 
8e 3,4-diCl-5-Me iPr CH3 COOH L 38 ± 9 nM 
8f 3,4-diCl-5-Me iPr CH3 COOH D 41 ± 16 nM 
8g 4,5-diBr CH2CH2NHBoc H COOH / 96% 
8h 4,5-diBr CH2CH2NHBoc Bn COOH L 100% 
8i 3,4-diCl-5-Me CH2CH2NHBoc CH3 COOH L 590 ± 20 nM 
9a 4,5-diBr CH2CH2NH3+Cl- Bn COOMe L 85% 
9b 3,4-diCl-5-Me CH2CH2NH3+Cl- CH3 COOMe L 34 ± 1 nM 
9c 4,5-diBr CH2CH2NH3+Cl- H COOH L 50% 
9d 4,5-diBr CH2CH2NH3+Cl- Bn COOH L 370 ± 10 nM 
9e 3,4-diCl-5-Me CH2CH2NH3+Cl- CH3 COOH L 28 ± 7 nM 
10a 3,4-diCl-5-Me iPr CH3 CONHNH2 L 280 ± 80 nM 
10b 3,4-diCl-5-Me CH2CH2NHBoc CH3 CONHNH2 L 68% 
11a 3,4-diCl-5-Me iPr CH3 
 
L 85 ± 7 nM 
11b 3,4-diCl-5-Me CH2CH2NHBoc CH3 
 
L 1600 ± 200 nM 
12 3,4-diCl-5-Me CH2CH2NH3+Cl- CH3 
 
L 13 ± 4 nM 
15a 4,5-diBr iPr H 
 
/ 100% 
15b 4,5-diBr iPr H 
 
/ 87% 
novobiocin    
 
 170 ± 20 nM 
a Concentration of compound that inhibits the enzyme activity by 50%. b Residual activity of the enzyme at 1 µM of 
the compound. 
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Table 2. Inhibitory activity of type II compounds 22a-d and 23a-d against DNA gyrase from E. 
coli. 
 
Compd. R1 R2 R3 
IC50 (nM)a or RA (%)b 
E. coli gyrase 
22a 4,5-diBr Bn Me 100% 
22b 4,5-diBr CH2CH2N(Me)2 Me 88% 
22c 4,5-diBr iPr Me 91% 
22d 3,4-diCl-5-Me iPr Me 59% 
23a 4,5-diBr Bn H 88 ± 0 nM 
23b 4,5-diBr CH2CH2NH(Me)2+Cl- H 82% 
23c 4,5-diBr iPr H 400 ± 90 nM 
23d 3,4-diCl-5-Me iPr H 91 ± 29 nM 
novobiocin    170 ± 20 nM 
a Concentration of compound that inhibits the enzyme activity by 50%. b Residual activity of the 
enzyme at 1 µM of the compound. 
 
Table 3. Inhibitory activity of selected compounds against DNA gyrase from S. aureus and 
topoisomerase IV from E. coli and S. aureus. 
Compd. 
IC50 (µM)a or RA (%)b 
S. aureus gyrase E. coli topo IV S. aureus topo IV 
8c 5.9 ± 0.7 µM 78% 98% 
8e 0.093 ± 0.065 µM 0.45 ± 0.12 µM 0.28 ± 0.20 µM 
8f 1.6 ± 0.6 µM 7.4 ± 1.5 µM 1.3 ± 0.1 µM 
8i 1.3 ± 0.0 µM 100% 99% 
9b 0.39 ± 0.09 µM 89% 3.7 ± 0.3 µM 
9d 89% 96% 98% 
9e 0.11 ± 0.04 µM 0.53 ± 0.06 µM 3.2 ± 0.4 µM 
10a 22 ± 10 µM 100% 92% 
11a 0.75 ± 0.15 µM 11 ± 0 µM 12 ± 0 µM 
12 1.0 ± 0.3 µM 0.57 ± 0.16 µM 0.96 ± 0.09 µM 
23a 79% 42 ± 11 µM 39 ± 0 µM 
23c 85% 100 % 96% 
23d 0.14 ± 0.02 µM 100% 12 ± 0 µM 
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novobiocin 0.041 ± 0.07 µM 11 ± 2 µM 27 ± 7 µM 
a Concentration of compound that inhibits the enzyme activity by 50%. b Residual 
activity of the enzyme at 1 µM of the compound. 
 
Antibacterial Activity. Compounds were tested for their antibacterial activity against two 
Gram-positive (S. aureus ATCC 25923 and E. faecalis ATCC 29212) and two Gram-negative (E. 
coli ATCC 25922 and P. aeruginosa ATCC 27853) wild type bacterial strains and, additionally, 
against two E. coli mutant strains (JW5503 ∆tolC and JD17464 ∆lpxC) at inhibitor 
concentrations of 50 µM. The tolC deletion mutant represents Gram-negative bacteria with 
defective efflux mechanisms and the lpxC deletion mutant represents a Gram-negative strain with 
disrupted bacterial cell wall. Results are presented in Table 1S (Supporting information) as 
percentages of growth inhibition. For compounds that inhibited bacterial strain growth by ≥80%, 
MIC values were also determined (Table 4).  
Overall, the compounds displayed stronger inhibitory activity against Gram-positive than 
against Gram-negative bacteria. Nine compounds (8a, 8d, 8e, 8f, 9a, 9b, 10a, 11a and 11b) 
showed more than 80% growth inhibition of E. faecalis, and three (9a, 9b and 11a)  inhibited the 
growth of S. aureus by more than 80%. Compound 9b, with an aminoethoxy substituent on the 3-
position of the central benzene ring, inhibited the growth of wild type E. coli by 67% (Table 1S) 
and completely suppressed the E. coli ∆tolC deletion mutant at 50 µM. For compounds 7c, 8e, 8f, 
9a, 11a and 12, significant differences in growth inhibition between wild type E. coli and the E. 
coli mutant strain having a defective efflux pump were also observed, while growth inhibition of 
the E. coli strain with impaired outer membrane was similar to that of the wild type for all 
compounds (Table 1S). These results suggest that some compounds are subject to bacterial 
efflux, which is probably the main reason for their weaker activity against Gram-negative 
bacteria. 
Compound 11a exhibited the strongest antibacterial activity of the series, with an MIC value of 
1.56 µM against E. faecalis, which is almost two-fold lower than that of ciprofloxacin (3 µM), 
and of 3.13 µM against S. aureus. Compound 11a, that contains an oxadiazolone ring in the 
eastern part of the molecule, was twice as active as its carboxylic acid analogue 8e (E. faecalis 
MIC = 3.13 µM) and four times more active than the corresponding hydrazide 10a (E. faecalis 
MIC = 6.25 µM). This result is in agreement with our design strategy that compounds with a less 
acidic and less polar bioisostere for the carboxylic acid group could permeate bacterial membrane 
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more easily and display stronger antibacterial activity. Compounds with an aminoethoxy 
substituent at the 3-position of the benzene ring (9a, 9b and 12) exhibited no or weaker activity 
against E. faecalis (MIC values >25 µM for 9a and 9b and no growth inhibition for compound 
12) than isopropoxy derivatives, presumably because the polarity of the amino group reduces the 
ability of compounds to enter the Gram-positive bacteria. Compounds containing both a free 
carboxylic acid group at the eastern part of the molecule and an aminoethoxy substituent at the 3-
position of the benzene ring (9c, 9d and 9e) were inactive against bacteria (less than 36% of 
growth inhibition, Table 1S) although compound 9e was among the most active in enzyme assays 
(S. aureus gyrase IC50 = 110 nM). On the other hand, compound 9b, a methyl ester analogue of 
9e with a higher IC50 value (S. aureus gyrase IC50 = 390 nM), inhibited the growth of Gram-
positive bacteria more strongly than 9e, with MIC values of 50 µM against S. aureus and 25 µM 
against E. faecalis (Table 4). Additionally, compound 9b showed a MIC value of 25 µM against 
an E. coli strain with defective efflux pump. Similar activities against an E. coli strain with a 
defective efflux pump were obtained for compound 9a (MIC = 25 µM) and for compound 12 
(MIC = 50 µM) that also contain an aminoethoxy substituent. These results suggest that the 
aminoethoxy substituent improves activity against Gram-negative bacteria, but the higher activity 
is not observed because the compounds are possible substrates for efflux pumps. 
 
Table 4. Minimum inhibitory concentrations (MICs) of compounds 7c, 8a, 8d, 8e, 8f, 9a, 9b, 
10a, 11a, 11b and 12 against S. aureus (ATCC 25923), E. faecalis (ATCC 29212) and E. coli 
(JW5503, a tolC deletion mutant). 
Compd. 
MIC (µM)a 
S. aureus (ATCC 25923) E. faecalis (ATCC 29212) E. coli (JW5503) ∆tolC b 
7c n.d.c n.d. 25 µM 
8a n.d. >75 µM n.d. 
8d n.d. 3.13 µM n.d. 
8e n.d. 3.13 µM 50 µM 
8f n.d. 6.25 µM n.d. 
9a 50 µM 50 µM 25 µM 
9b 50 µM 25 µM 25 µM 
10a n.d. 6.25 µM n.d. 
11a 3.13 µM 1.56 µM n.d. 
11b n.d. 100 µM n.d. 
12 n.d. n.d. 50 µM 
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ciprofloxacin 1.5 µM 3.0 µM 0.015 µM 
a MIC (minimum inhibitory concentration that inhibits the growth of bacteria by ≥ 90%) values 
against E. faecalis, S. aureus and E. coli JW5503 (∆tolC). Ciprofloxacin was used as a positive 
control. b E. coli strain with mutated efflux pump.  c Not determined. 
 
Advanced antibacterial evaluation of compound 11a. Compound 11a was selected as the 
most promising of the series, since it had the low nanomolar IC50 values in enzyme tests and the 
lowest MIC values against Gram-positive strains of all the compounds. For this reason, 
compound 11a was further evaluated against a diverse panel of Gram-positive and Gram-
negative bacterial strains (Table 5). In line with our previous observations, compound 11a 
displayed an MIC value of 4.17 µM against the Gram-positive human pathogen S. aureus ATCC 
29213. Furthermore, it was active against methicillin-resistant Staphylococcus aureus (MRSA, 
ATCC 43300) and vancomycin-resistant Enterococcus (VRE, ATCC 70022), with MICs of 3.13 
µM (Table 5). On the other hand, compound 11a displayed no bioactivity against wild type E. 
coli strains (ATCC 25922, MG1655 and BW 25113). We therefore sought to explore 
systematically the limiting factors for lack of anti-Gram-negative activity of compound 11a. To 
investigate possible difficulties with its penetration into the bacterial cell, we tested compound 
11a on a diverse panel of mutant E. coli strains carrying loss-of-function mutations in either 
dapF, mrcB or surA genes that disrupt the bacterial cell wall integrity [27]. As a parallel 
approach, to test the susceptibility of compounds to efflux, we treated the parental strains and 
their corresponding mutants with an efflux pump inhibitor phenylalanine-arginine β-
naphthylamide (PAβN), which is in fact not a typical inhibitor but a substrate for efflux pumps 
that is preferentially effluxed. Furthermore, we tested compound 11a against E. coli BW 25113 
∆acrB and ∆tolC deletion mutants with defective efflux pumps. Mutations in the genes involved 
in the formation of the cell wall (dapF, mrcB and surA) did not increase the antibacterial activity 
(MIC > 50 µM) but, in the case of ∆surA strain, stronger inhibition was observed in the presence 
of PAβN (MIC = 13.8 µM). The presence of PAβN also increased the activity against wild type 
E. coli strains ATCC 25922 (MIC = 4.6 µM) and MG1655 (MIC = 10.2 µM). Compound 11a did 
not inhibit the efflux pump deficient E. coli BW 25113 strains ∆acrB and ∆tolC (MIC > 50 µM, 
Table 5), but it displayed weak activity against the E. coli JW5503 ∆tolC strain (51% inhibition 
at 50 µM, Table 1S). These results indicate that the most probable reason for the inactivity of 
compound 11a against Gram-negative strains lies in bacterial efflux. 
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Additionally, in order to validate the interaction between the oxadiazolone ring of 11a and 
Arg136 in the DNA gyrase binding site, compound 11a was tested, in the presence of PAβN, on 
E. coli MG1655 strain with the Arg136 to Cys mutation.. The compound was not active on the 
mutated bacteria (MIC > 50 µM), but displayed activity against wild type E. coli in the presence 
of PAβN (MIC = 10.2 µM), indicating that the compound interacts with Arg136. 
 
Table 5. Minimum inhibitory concentrations (MICs) of compound 11a against a broad panel of 
Gram-positive and Gram-negative bacterial strains. 
 
 
Cytotoxic activity of compound 11a. The cytotoxicity of compound 11a was determined by 
MTS assay against a human hepatocellular carcinoma cancer cell line (HepG2) and against 
human endothelial cells (HUVEC). The decrease in cell proliferation after the treatment with 11a 
Compound 11a MIC (µM)a 
Gram-positive bacteria  
S. aureus (ATCC 29213) 4.17 µM 
S. aureus (MRSA, ATCC 43300) 3.13 µM 
E. faecium (VRE, ATCC 70022) 3.13 µM 
Gram-negative bacteria  
E. coli (ATCC 25922)   No inhibition up to 50 µM 
E. coli (MG1655)  No inhibition up to 50 µM 
E. coli (BW 25113) No inhibition up to 50 µM 
E. coli (BW 25113) ∆tolCb No inhibition up to 50 µM 
E. coli (BW 25113) ∆acrBb No inhibition up to 50 µM 
E. coli (BW 25113) ∆dapFc No inhibition up to 50 µM 
E. coli (BW 25113) ∆mrcBc No inhibition up to 50 µM 
E. coli (BW 25113) ∆surAc No inhibition up to 50 µM 
E. coli (ATCC 25922) + 50 µg/ml PAβN 4.6 µM 
E. coli (MG1655) + 50 µg/ml PAβN 10.2 µM 
E. coli (BW 25113) + 50 µg/ml PAβN No inhibition up to 20 µM  
E. coli (BW 25113) ∆dapFc + 50 µg/ml PAβN No inhibition up to 20 µM 
E. coli (BW 25113) ∆mrcBc + 50 µg/ml PAβN No inhibition up to 20 µM 
E. coli (BW 25113) ∆surAc + 50 µg/ml PAβN 13.8 µM 
E. coli (MG1655) R136-to-C mutant + 50 µg/ml PAβN No inhibition up to 50 µM 
a MIC (minimum inhibitory concentration that inhibits the growth of bacteria by ≥ 90%) 
measurements were performed according to the EUCAST guidelines in 3 independent 
measurements. b E. coli strain with mutated efflux pump. c E. coli strain with loss-of-function 
mutation in the gene involved in the cell wall formation. 
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was compared with that after treatment with 50 µM of etoposide, as positive control. Compound 
11a showed no cytotoxicity against HepG2 cells at 50 µM (85% cell proliferation), while it 
showed an IC50 value of 40.7 µM against HUVEC cells (Table 2S, Supporting information). 
However, the concentration at which the compound was active against HUVEC cells was much 
higher than that at which it is active against Gram-positive bacteria. 
  
CONCLUSIONS 
Overall, thirty-eight compounds were designed, synthesized and evaluated against DNA gyrase 
and topoisomerase IV, and against several Gram-positive and Gram-negative bacterial strains. 
The most active compound in enzymatic assays was 3,4-dichloro-5-methyl-pyrrolamide 8e, with 
an isopropoxy substituent at the 3-position of the benzene ring and a free carboxylic acid 
functionality in the eastern part of the molecule. Compound 8e had an IC50 value of 38 nM 
against E. coli gyrase and 93 nM against S. aureus gyrase, and was also active against E. coli 
topo IV (IC50 = 0.45 µM) and S. aureus topo IV (IC50 = 0.28 µM). Compound 11a, an 
oxadiazolone analogue of 8e, possessed low micromolar antibacterial activity against Gram-
positive bacteria, with MIC values of 1.56 µM and 3.13 µM against E. faecalis and S. aureus, 
respectively. Further, compound 11a inhibited the growth of MRSA and VRE, key targets for 
antibiotic research, with MIC values of 3.13 µM [28]. Compound 11a was not active against wild 
type E. coli strains, but was active in the presence of PAβN (MIC = 4.6 µM). These results 
suggest that, in Gram-negative bacteria, the compounds are sensitive to the efflux mechanism. In 
recent years, however, new compounds that can be used as adjuvants to potentiate the activity of 
antibiotics against Gram-negative strains are becoming available [29]. In short, low nanomolar 
enzymatic activity against DNA gyrase and topo IV, low micromolar MIC values against drug-
resistant Gram-positive bacteria, and low cytotoxicity make compound 11a a promising starting 
point for further optimisation. 
 
EXPERIMENTAL SECTION 
Determination of Inhibitory Activities on E. coli and S. aureus DNA Gyrase. The assay for 
the determination of IC50 values was performed according to previously reported procedures [16]. 
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Determination of Inhibitory Activities on E. coli and S. aureus Topoisomerase IV. The 
assay for the determination of IC50 values was performed according to previously reported 
procedures [16]. 
Bacterial strains used in the study. 
Staphylococcus aureus ATCC 29213, Staphylococcus aureus ATCC 25923, S. aureus  ATCC 
43300, Enterococcus faecalis ATCC 29212, Enterococcus faecium ATCC 70022, Escherichia 
coli ATCC 25922, and Pseudomonas aeruginosa ATCC 27853 have been obtained from the 
American Type Culture Collection (ATCC) via Microbiologics Inc. (St. cloud, MN), E. coli 
MG1655 originated from the laboratory collection of Dr. Csaba Pál. E. coli BW 25113, and E. 
coli BW 25113 ∆acrB, ∆dapF, ∆mrcB and ∆surA mutant strains originated from the KEIO 
collection [30]. Single-gene knock-out strains of E. coli, JW5503 ∆tolC [30] and JD17464 ∆lpxC 
were obtained from the NBRP-E.coli collection at the National Institute of Genetics (NIG, 
Japan). 
Determination of Antibacterial Activity. 
The antibacterial activities against S. aureus ATCC 25923, E. faecalis ATCC 29212, E. coli 
ATCC 25922, P. aeruginosa ATCC 27853, E. coli JW5503, E. coli JD17464, S. aureus  ATCC 
43300, and E. faecium ATCC 70022 were determined following the CLSI guidelines and 
performed according to previously reported procedures [16]. 
MIC values against S. aureus ATCC 29213, E. coli ATCC 25922, E. coli MG1655, E. coli BW 
25113, and E. coli BW 25113 ∆acrB, ∆dapF, ∆mrcB and ∆surA were determined using a 
standard broth microdilution technique according to the EUCAST guidelines and ISO 20776-
1:2006 [31]. In brief, 12-step serial dilutions of the test compound were prepared in 100 µL of 
cation adjusted Mueller-Hinton II Broth (Catalog n.o. 90922 from Merck KGaA, Darmstadt, 
Sigma) in 96-well microtiter plates. Approximately 5x104 bacteria were inoculated onto each 
well. Plates were incubated at 37 °C and shaken at 300 r.p.m. Measurements were performed in 3 
replicates. After 18 h of incubation, optical density values were measured in a Biotek Synergy 
microplate reader at 600 nm wavelength for each well. MIC values were defined as the lowest 
concentration of the test substance where no visible growth can be observed, i.e. the background-
normalized optical density of the culture at 600 nm was below 0.05. 
In vitro cytotoxicity measurements. Cytotoxicity of compound 11a was determined in MTS 
(3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) 
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assay [32] with a few modifications. HepG2 (ATCC) and HUVEC (ATCC) cells were cultured in 
Eagle's MEM medium supplemented with L-glutamine (2 mM), penicillin/streptomycin (100 
UI/mL/100 µg/mL), and 10% FBS. The cells were incubated in a humidified atmosphere with 5% 
CO2 at 37 °C. 
The cells were seeded in 96-well plates at densities 2000 cells per well in 100 µL of growth 
medium and incubated for 24 h to attach onto the wells. 50 µL of compounds at 50 µM in DMSO 
(0.5% final concentration) were added and incubated for 72 h. After 72 h 10 µL of CellTiter96® 
Aqueous One Solution Reagent, (Promega) [33] was added to determine the number of viable 
cells. The plates were incubated for another 3 h and absorbance (490 nm) was read with a 
BioTek's Synergy H4 microplate reader. Etoposide [IC50 = 20.1 µM (Ref. [34]: 30.2 µM) for 
HepG2 and IC50 = 5.21 µM (Ref. [35]: 1.25 µM) for HUVEC] at 50 µM was used as a positive 
control and 0.5% DMSO as a vehicle control. To determine cell viability, results from the wells 
that contained test compound-treated cells were compared to those with cells incubated in 0.5% 
DMSO. Independent experiments were run in triplicate and repeated two times. Statistical 
significance (p < 0.05) was calculated with two-tailed Welch's t test between treated groups and 
DMSO. On HUVEC cell line, where compound showed higher activity, IC50 value (concentration 
of compound that inhibits cell proliferation by 50%) was determined using six concentrations of 
the tested compound. GraphPad Prism 5.0 software [36] was used to calculate the IC50 value. 
Molecular Modeling. 
Protein and Ligand Preparation. 3D compound models were built using ChemBio3D Ultra 16.0 
[37]. MMFF94 force field [38] was used for the optimization of geometries and partial atomic 
charges were added. Energy was minimized to less than 0.001 kcal/(mol Å) gradient value. The 
structure was refined with GAMESS interface using PM3 method, QA optimization algorithm 
and Gasteiger Hückel charges for all atoms for 100 steps [37]. GOLD Suite v5.4 [23, 39] was 
used for molecular docking calculations. GOLD graphical user interface was used for receptor 
preparation. To the protein hydrogen atoms were added and correct tautomers and protonation 
states were assigned. Except for HOH614, all water molecules and ligands were deleted from the 
crystal structure. Amino acid residues within 7 Å around the ligand (PDB entry: 4DUH [22]) 
were selected as the binding site. 
Ligand Docking. Compounds were docked to the defined binding site in 25 independent 
genetic algorithm (GA) runs by applying different GA parameters (population size = 100, 
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selection pressure = 1.1, number of operations = 100,000, niche size = 2, number of islands = 5, 
mutation frequency = 95, crossover frequency = 95, migration frequency = 10) and scoring 
functions (GoldScore, ChemScore, CHEMPLP). The most representative results were obtained 
using GoldScore as a scoring function. Ligands with RMSD value less than 1.5 Å were joined in 
clusters and early termination was allowed if the top 3 solutions were within 1.0 Å of the RMSD 
value. Proposed binding modes of the top 5 highest scored docking poses were evaluated for each 
ligand and the highest scored pose was used for graphical representation with PyMOL [24]. 
Chemistry. Chemicals were obtained from Acros Organics (Geel, Belgium), Sigma-Aldrich 
(St. Louis, MO, USA) and Apollo Scientific (Stockport, UK) and used without further 
purification. Analytical TLC was performed on silica gel Merck 60 F254 plates (0.25 mm), using 
visualization with UV light and spray reagents. Column chromatography was carried out on silica 
gel 60 (particle size 240–400 mesh). HPLC analyses were performed on an Agilent Technologies 
1100 instrument (Agilent Technologies, Santa Clara, CA, USA) with a G1365B UV-Vis detector, 
a G1316A thermostat, a G1313A autosampler, and a ChemStation data system or on a Thermo 
Scientific Dionex Ultimate 3000 Binary Rapid Seperation LC System (Thermo Fisher Scientific, 
Waltham, MA, USA) with an autosampler, a binary pump system, a photodiode array detector, a 
thermostated column compartment, and a Chromeleon Chromatography Data System. The eluent 
for consisted of trifluoroacetic acid (0.1% in water) or 20 mM phosphate buffer (pH 6.8) as 
solvent A and acetonitrile as solvent B. Two methods were used, method A: Agilent Eclipse Plus 
C18 column (5 µm, 4.6 mm × 150 mm), mobile phase of 30-90% of acetonitrile in TFA (0.1%) in 
16 min, 90% acetonitrile to 20 min, a flow rate of 1.0 mL/min and a sample injection volume of 
10 µL, and method B: Phenomenex Luna C18 column (5 µm, 4.6 mm × 250 mm), mobile phase 
of 50-80% of acetonitrile in 20 mM phosphate buffer (pH 6.8) in 30 min, a flow rate of 1.0 
mL/min and a sample injection volume of 10 µL. Melting points were determined on a Reichert 
hot stage microscope and are uncorrected. 1H and 13C NMR spectra were recorded at 400 and 100 
MHz, respectively, on a Bruker AVANCE III 400 spectrometer (Bruker Corporation, Billerica, 
MA, USA) in DMSO-d6, CDCl3 or acetone–d6 solutions, with TMS as the internal standard. IR 
spectra were recorded on a Thermo Nicolet Nexus 470 ESP FT-IR spectrometer (Thermo Fisher 
Scientific, Waltham, MA, USA). Mass spectra were obtained using a Q-TOF Premier mass 
spectrometer (Micromass, Waters, Manchester, UK) or ADVION expression CMSL mass 
spectrometer (Advion Inc., Ithaca, USA). Optical rotations were measured on a Perkin-Elmer 241 
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MC polarimeter. The reported values for specific rotation are average values of 10 successive 
measurements using an integration time of 5 s. The purity of the tested compounds was ≥ 95% as 
established by HPLC. 
Synthetic Procedures. 
General procedure A. Synthesis of Compounds 2 and 17 (with 2 as an Example). To a suspension 
of 3-hydroxy-4-nitrobenzoic acid (1) (5.00 g, 27.3 mmol) in methanol (150 mL) cooled on ice 
bath thionyl chloride (5.90 mL, 81.9 mmol) was added dropwise. The mixture was stirred at rt for 
15 h upon which a clear solution formed. The solvent was evaporated under reduced pressure. To 
the residue petroleum ether (50 mL) was added, the obtained suspension was sonicated, filtered 
and washed with petroleum ether (20 mL). The purification was repeated twice and the residue 
was dried to give compound 2 (4.92) as yellow crystals. 
Methyl 3-hydroxy-4-nitrobenzoate (2) [40]. Yellow crystals; yield 92 % (4.92 g); mp 87-88 °C 
(86-88 °C, lit.[40]). IR (ATR) ν = 3309, 3053, 2961, 1720, 1623, 1586, 1434, 1321, 1220, 1146, 
1097, 966, 842, 798, 743, 667 cm-1. 1H NMR (400 MHz, CDCl3) δ 3.99 (s, 3H, CH3), 7.64 (dd, 
1H, 3J = 8.8 Hz, 4J = 1.6 Hz, Ar-H-6), 7.86 (d, 1H, 4J = 1.6 Hz, Ar-H-2), 8.20 (d, 1H, 3J = 8.8 Hz, 
Ar-H-5), 10.53 (s, 1H, OH). 
General procedure B. Synthesis of Compounds 3a and 18c (with 3a as an Example). To a stirred 
solution of compound 2 (3.00 g, 15.2 mmol) and triphenylphosphine (5.40 g, 20.6 mmol) in 
anhydrous tetrahydrofuran (30 mL) isopropanol (1.5 mL, 19.8 mmol) was added and the mixture 
was stirred at rt for 10 minutes. Diisopropyl azodicarboxylate (DIAD, 3.90 mL, 19.8 mmol) was 
added dropwise and the mixture was stirred at rt for 15 h under argon atmosphere. The solvent 
was evaporated under reduced pressure and the crude product was purified with flash column 
chromatography using ethyl acetate/petroleum ether (1/6) as an eluent to give 3a (3.50 g) as 
yellow solid.  
Methyl 3-isopropoxy-4-nitrobenzoate (3a). Yellow solid; yield 97% (3.50 g); mp 42-44 °C 
(39-41 °C, lit.[41]). IR (ATR) ν = 3117, 2989, 2950, 1724, 1610, 1525, 1422, 1284, 1103, 1004, 
942, 835, 741 cm-1. 1H NMR (400 MHz, DMSO-d6) δ 1.30 (d, 6H, 3J = 6.0 Hz, CH(CH3)2), 3.91 
(s, 3H, COOCH3), 4.93 (spt, 1H, 3J = 6.0 Hz, CH(CH3)2), 7.64 (dd, 1H, 3J = 8.4 Hz, 4J = 1.6 Hz, 
Ar-H-6), 7.78 (d, 1H, 4J = 1.2 Hz, Ar-H-2), 7.95 (d, 1H, 3J = 8.0 Hz, Ar-H-5). 
General procedure C. Synthesis of Compounds 4a-b and 19a-c (with 4a as an Example). To the 
solution of compound 3a (3.50 g, 14.6 mmol) in methanol (30 mL) 1 M NaOH (28 mL, 29.3 
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mmol) was added. The mixture was stirred at rt for 15 h. The solvent was removed under reduced 
pressure and the residue acidified with 1M HCl (10 mL). Water phase was extracted with ethyl 
acetate (3 × 20 mL).  The combined organic phases were washed with water (3 × 20 mL) and 
brine (2 × 20 mL), dried over Na2SO4, filtered and the solvent removed under reduced pressure to 
afford 4a (3.00 g) as yellow solid.  
3-Isopropoxy-4-nitrobenzoic acid (4a). Yellow solid; yield 91% (3.00 g); mp 170-173 °C 
(173-175°C, lit.[41]). IR (ATR) ν = 1987, 2838, 2603, 1689, 1522, 1427, 1296, 110, 937, 837, 
742 cm-1. 1H NMR (400 MHz, DMSO-d6) δ 0.86 (d, 6H, 3J = 6.0 Hz, CH(CH3)2), 4.46 (spt, 1H, 
3J = 6.0 Hz, CH(CH3)2), 7.17 (dd, 1H, 3J = 8.0 Hz, 4J = 1.6 Hz, Ar-H-6), 7.32 (d, 1H, 4J = 1.6 Hz, 
Ar-H-2), 7.48 (d, 1H, 3J = 8.4 Hz, Ar-H-5), 13.21 (s, 1H, COOH). 
General procedure D. Synthesis of Compounds 5a-g, 13a-c and 20a-b (with 5a as an Example). 
To the suspension of 4a (800 mg, 3.55 mmol) and TBTU (1.48 g, 4.62 mmol) in dichloromethane 
(40 mL) N-methylmorpholine (1.2 mL, 10.7 mmol) was added. The reaction mixture was stirred 
at rt for 30 minutes upon which a clear solution formed. L-valine methyl ester hydrochloride (715 
mg, 4.26 mmol) was added and the mixture was stirred at rt for 15 h. The solvent was removed 
under reduced pressure and the residue was dissolved in ethyl acetate (30 mL) and water (30 
mL). The organic phase was washed with saturated aqueous NaHCO3 solution (3 × 20 mL) and 
brine (2 × 20 mL), dried over Na2SO4, filtered and the solvent evaporated under reduced pressure 
to give 5a (1.11 g) as yellow oil.  
Methyl (3-isopropoxy-4-nitrobenzoyl)-L-valinate (5a). Yellow oil; yield 92% (1.11 g); [α]D25 
-8.32 (c 0.263, MeOH). IR (ATR) ν = 3279, 2974, 1744, 1640, 1533, 1317, 1256, 1103, 1021, 
842, 748 cm-1. 1H NMR (400 MHz, CDCl3) δ 1.00-1.04 (m, 6H, CHCH(CH3)2), 1.42 (d, 6H, 3J = 
6 Hz, OCH(CH3)2), 2.27-2.35 (m, 1H, CHCH(CH3)2), 3.81 (s, 3H, COOCH3), 4.75-4.82 (m, 2H, 
CHCH(CH3)2, OCH(CH3)2), 6.71 (d, 1H, 3J = 8.4 Hz, NH), 7.31 (dd, 1H, 3J = 8.4 Hz, 4J = 1.6 
Hz, Ar-H-6), 7.62 (d, 1H, 4J = 1.2 Hz, Ar-H-2), 7.81 (d, 1H, 3J = 8.0 Hz, Ar-H-5). 13C NMR (100 
MHz, DMSO-d6) δ 19.01 (CH3), 19.10 (CH3), 21.50 (CH(CH3)2), 21.56 (CH(CH3)2), 29.60 (CH), 
51.75 (COOCH3), 58.77 (CH), 72.43 (CH), 115.32, 119.76, 124.62, 138.42, 142.29, 149.61, 
165.28 (CONH), 171.97 (COOCH3). 
General procedure E. Synthesis of Compounds 6a-g, 14b-c and 21a-b (with 6a as an Example). 
Compound 5a (1.11 g, 3.28 mmol) was dissolved in methanol (40 mL), Pd/C (111 mg) was 
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added and the reaction mixture was stirred under hydrogen atmosphere for 3 hours. The catalyst 
was filtered off and the solvent removed under reduced pressure.  
Methyl (4-amino-3-isopropoxybenzoyl)-L-valinate (6a). The crude product was purified with 
flash column chromatography using ethyl acetate/petroleum ether (1/1) as an eluent to obtain 6a 
(522 mg) as yellow oil. Yield: 55% (522 mg). [α]D25 -5.53 (c 0.378, MeOH). 1H NMR (400 MHz, 
CDCl3) δ 0.99-1.03 (m, 6H, CHCH(CH3)2), 1.38 (d, 6H, 3J = 6.4 Hz, OCH(CH3)2), 2.23-2.31 (m, 
1H, CHCH(CH3)2), 3.79 (s, 1H, COOCH3), 4.11-4.17 (m, 2H NH2), 4.66 (spt, 1H, 3J = 6.0 Hz, 
OCH(CH3)2), 4.76-4.79 (m, 1H, CHCH(CH3)2), 6.50 (d, 1H, 3J = 8.8 Hz, NH), 6.70 (d, 1H, 3J = 
8.0 Hz, Ar-H-5), 7.20 (dd, 1H, 3J = 8.0 Hz, 4J = 2.0 Hz, Ar-H-6), 7.40 (d, 1H, 4J = 2.0 Hz, Ar-H-
2). MS (ESI) m/z = 331.37 ([M+Na]+). 
General procedure F. Synthesis of Compounds 7a-i, 15a-d and 22a-b (with 7a as an Example). 
To a solution of 4,5-dibromo-1H-pyrrole-2-carboxylic acid (157 mg, 0.584 mmol) in anhydrous 
dichloromethane (4 mL) oxalyl chloride (2M solution in dichloromethane, 1.46 mL, 2.92 mmol) 
was added dropwise and the solution stirred at rt for 15 h under argon atmosphere. The solvent 
was evaporated under reduced pressure, fresh anhydrous dichloromethane (4 mL), 6a (150 mg, 
0.487 mmol) and pyridine (2 mL) were added and the reaction mixture stirred under argon 
atmosphere at rt for 15 h. Solvent was removed under reduced pressure, the residue dissolved in 
ethyl acetate (20 mL) and washed with water (20 mL), saturated aqueous NaHCO3 solution (3 × 
20 mL) and brine (2 × 20 mL). The organic phase was dried over Na2SO4, filtered and the solvent 
removed under reduced pressure.  
Methyl (4-(4,5-dibromo-1H-pyrrole-2-carboxamido)-3-isopropoxybenzoyl)-L-valinate 
(7a). To the crude product ethyl acetate and petroleum ether (1:2, 15 mL) were added and the 
precipitate was filtered off to obtain 7a (40 mg) as light brown solid. The mother liquid was 
concentrated and purified with flash column chromatography using ethyl acetate/petroleum ether 
(1/2) as an eluent to give another 61 mg of 7a as light brown solid. Yield 37% (101 mg); mp 145-
148 °C. [α]D25 +8.94 (c 0.273, MeOH). IR (ATR) ν = 3417, 3304, 3238, 2964, 1741, 1633, 1515, 
1418, 1311, 1202, 1124, 978, 831, 743 cm-1. 1H NMR (400 MHz, DMSO-d6) δ 0.94-1.00 (m, 6H, 
CHCH(CH3)2), 1.32-1.35 (m, 6H, OCH(CH3)2), 2.15-2.23 (m, 1H, CHCH(CH3)2), 3.67 (s, 3H, 
COOCH3), 4.30 (t, 1H, 3J = 8.0 Hz, CHCH(CH3)2), 4.72 (spt, 1H, 3J = 6.0 Hz, OCH(CH3)2), 7.18 
(d, 1H, 4J = 2.4 Hz, Pyrr-CH), 7.53-7.55 (m, 2H, Ar-H-2,6), 7.92 (d, 1H, 3J = 8.4 Hz, Ar-H-5), 
8.59 (d, 1H, 3J = 8.0 Hz, CONHCH), 9.06 (s, 1H, CONHAr), 13.02 (d, 1H, 4J = 2.8 Hz, Pyrr-
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NH). 13C NMR (100 MHz, DMSO-d6) δ 19.06 (CHCH(CH3)2), 19.09 (CHCH(CH3)2), 21.59 
(OCH(CH3)2), 21.67 (OCH(CH3)2), 29.45 (CHCH(CH3)2), 51.55 (COOCH3), 58.59 
(CHCH(CH3)2), 71.29 (OCH(CH3)2), 98.35, 106.22, 113.18, 113.77, 120.11, 122.44, 127.50, 
130.06, 130.50, 148.15, 156.95, 166.15 (Ar-CONH), 172.26 (COOCH3). MS (ESI) m/z = 556.0 
([M-H]-), HRMS for C21H24Br2N3O5: calculated 556.0083, found 556.0076. HPLC: tr 14.108 min 
(97.2% at 280 nm, method A). 
General procedure G. Synthesis of Compounds 8a-e, 8g-i and 23a-d (with 8a as an Example). To 
the solution of 7a (65 mg, 0.116 mmol) in tetrahydrofuran (8 mL) 1 M NaOH (348 µL, 348 
µmol) was added and the mixture was stirred at rt for 15 h. The solvent was evaporated under 
reduced pressure, the residue acidified with 1 M HCl (5 mL) to pH 1 and the water phase was 
extracted with ethyl acetate (3 × 10 mL). The combined organic phases were washed with water 
(3 × 10 mL) and brine (10 mL), dried over Na2SO4, filtered and the solvent removed under 
reduced pressure to obtain 8a (53 mg) as white solid.  
(4-(4,5-Dibromo-1H-pyrrole-2-carboxamido)-3-isopropoxybenzoyl)-L-valine (8a). White 
solid; yield 87% (53 mg); mp 116-120 °C; [α]D25 +18.6 (c 0.288, MeOH). IR (ATR) ν = 3402, 
3183, 2970, 1716, 1648, 1507, 1389, 1265, 1179, 1109, 977, 805, 751 cm-1. 1H NMR (400 MHz, 
DMSO-d6) δ 0.96-1.00 (m, 6H, CHCH(CH3)2), 1.32-1.36 (m, 6H, OCH(CH3)2), 2.15-2.22 (m, 
1H, CHCH(CH3)2), 4.30 (t, 1H, 3J = 8.0 Hz, CHCH(CH3)2), 4.73 (spt, 1H, 3J = 5.6 Hz, 
OCH(CH3)2), 7.18 (d, 1H, 4J = 2.4 Hz, Pyrr-CH), 7.53-7.57 (m, 2H, Ar-H-2,6), 7.92 (d, 1H, 3J = 
8.0 Hz, Ar-H-5), 8.42 (d, 1H, 3J = 8.0 Hz, CONHCH), 9.05 (s, 1H, CONHAr), 12.62 (br s, 1H, 
COOH), 13.02 (s, 1H, Pyrr-NH).  13C NMR (100 MHz, DMSO-d6) δ 18.89 (CHCH(CH3)2), 
19.34 (CHCH(CH3)2), 21.67 (OCH(CH3)2), 21.76 (OCH(CH3)2), 29.52 (CHCH(CH3)2), 58.38 
(CHCH(CH3)2), 71.36 (OCH(CH3)2), 98.41, 106.28, 113.28, 113.82, 120.16, 122.53, 127.60, 
130.43, 130.46, 148.22, 157.03, 166.13 (Ar-CONH), 173.22 (COOH). MS (ESI) m/z = 542.0 
([M-H]-), HRMS for C20H22Br2N3O5: calculated 541.9926, found 541.9935. HPLC: tr 12.049 min 
(98.1% at 280 nm, method A). 
General procedure H. Synthesis of Compounds 9a-e (with 9a as an Example). The starting 
compound (7h, 40 mg, 0.057 mmol) was dissolved in 4 M HCl in 1,4-dioxane (4 mL) and 
tetrahydrofuran (1 mL) and the reaction mixture stirred at rt for 2 hours. The solvent was 
removed under reduced pressure, to the residue diethyl ether (10 mL) was added, the obtained 
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suspension was sonicated, filtered, washed with diethyl ether (2 × 2 mL) and dried to give 9a (36 
mg) as white solid.  
(S)-2-(2-(4,5-Dibromo-1H-pyrrole-2-carboxamido)-5-((1-methoxy-1-oxo-3-phenylpropan-
2-yl)carbamoyl)phenoxy)ethan-1-aminium chloride (9a). White solid; yield 99 % (36 mg); mp 
146-148 °C; [α]D25 -48.7 (c 0.252, MeOH). IR (ATR) ν = 3394, 3326, 3222, 3029, 2951, 2859, 
1723, 1649, 1509, 1414, 1277, 1179, 1021, 972, 816, 746, 700 cm-1. 1H NMR (400 MHz, 
DMSO-d6) δ 3.09-3.21 (m, 2H, CH2Ph), 3.38-3.43 (m, 2H, OCH2CH2NH, overlapping with the 
signal for water), 3.65 (s, 3H, CH3), 4.30 (t, 2H, 3J = 4.4 Hz, OCH2CH2NH), 4.64-4.70 (m, 1H, 
CH), 7.18-7.36 (m, 6H, 5 × Ar-H, Pyrr-CH), 7.48 (d, 1H, 4J = 1.6 Hz, Ar-H), 7.51 (dd, 1H, 3J = 
8.4 Hz, 4J = 1.6 Hz, Ar-H), 8.03 (d, 1H, 3J = 8.4 Hz, Ar-H), 8.25 (s, 3H, NH3+), 8.89 (d, 1H, 3J = 
8.0 Hz, CONHCH), 9.44 (s, 1H, CONHAr), 13.10 (d, 1H, 4J = 2.4 Hz, Pyrr-NH). 13C NMR (100 
MHz, DMSO-d6) δ  36.25 (CH2), 38.35 (CH2), 51.95 (CH3), 54.33 (CH), 64.84 (CH2), 98.41, 
106.29, 110.57, 115.03, 120.24, 122.13, 126.49, 127.47, 128.24, 129.07, 129.51, 129.53, 137.66, 
147.98, 157.29, 165.54 (Ar-CONH), 172.21 (COOH). MS (ESI) m/z = 605.0 ([M-H]-). HRMS 
for C24H23Br2N4O5: calculated 605.0035, found 605.0018. HPLC: tr 8.015 min (95.0 % at 220 
nm, 95.3 % at 280 nm, method A). 
General procedure I. Synthesis of Compounds 10a-b (with 10a as an Example). To the solution 
of 7e (180 mg, 0.395 mmol) in anhydrous methanol and anhydrous tetrahydrofurane (3:1, 16 mL) 
hydrazine monohydrate (240 µL, 3.95 mmol) was added and the reaction mixture stirred at 65 °C 
for 15 h. The obtained suspension was cooled on ice bath, the precipitate filtered off and dried to 
give 10a (104 mg) as white solid.  
(S)-3,4-Dichloro-N-(4-((1-hydrazineyl-1-oxopropan-2-yl)carbamoyl)-2-
isopropoxyphenyl)-5-methyl-1H-pyrrole-2-carboxamide (10a). White solid; yield 58% (104 
mg); mp 235-237 °C. [α]D25 +87.9 (c 0.220, DMF). IR (ATR) ν = 3397, 3365, 3310, 3252, 3134, 
2984, 2940, 1733, 1648, 1518, 1441, 1324, 1261, 1173, 1042, 990, 831, 747, 702 cm-1. 1H NMR 
(400 MHz, DMSO-d6) δ 1.32-1.38 (m, 9H, CH3, CH(CH3)2), 2.24 (s, 3H, Pyrr-CH3), 4.23 (s, 2H, 
NH2), 4.47 (quint, 1H, 3J = 7.2 Hz, CONHCH), 4.88 (spt, 1H, 3J = 6.0 Hz, CH(CH3)2), 7.56 (dd, 
1H, 3J = 8.4 Hz, 4J = 1.6 Hz, Ar-H-6), 7.64 (d, 1H, 4J = 1.6 Hz, Ar-H-2), 8.44-8.48 (m, 2H, Ar-
H-5, CONHCH), 9.18 (s, 1H, NHNH2), 9.25 (s, 1H, CONHAr), 12.45 (s, 1H, Pyrr-NH); 13C 
NMR (100 MHz, DMSO-d6) δ 10.75 (Pyrr-CH3), 18.16 (CH3), 21.78 (CH(CH3)2), 21.84 
(CH(CH3)2), 47.67 (CH), 71.28 (CH(CH3)2), 108.58, 109.67, 111.89, 117.87, 118.66, 120.65, 
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128.92, 129.75, 131.01, 145.05, 156.19, 165.22 (Ar-CONH), 171.77 (CONHNH2). MS (ESI) m/z 
= 454.1 ([M-H]-). HRMS for C19H22Cl2N5O4: calculated 454.1049, found 454.1041. HPLC: tr 
9.111 min (95.8 % at 254 nm, method A). 
General procedure J. Synthesis of Compounds 11a-b (with 11a as an Example). To the solution 
of 10a (83 mg, 0.172 mmol) in 1,4-dioxane and anhydrous dimethylformamide (2:1, 7.5 mL) 
1,1'-carbonyldiimidazole (CDI, 55.8 mg, 0.344 mmol) was added and the reaction mixture was 
stirred at 101 °C for 15 h. Additional 0.5 equivalents of 1,1'-carbonyldiimidazole (14 mg, 0.0863 
mmol) were added and the mixture was stirred at 101 °C for 1 hour. The solvent was removed 
under reduced pressure. 
(S)-3,4-Dichloro-N-(2-isopropoxy-4-((1-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-
yl)ethyl)carbamoyl)phenyl)-5-methyl-1H-pyrrole-2-carboxamide (11a). To the residue 
acetonitrile (10 mL) was added, the obtained suspension was sonicated and filtered. To the 
precipitate water (10 mL) was added, the suspension was sonciated, filtered, washed with water 
(2 × 5 mL) and dried to obtain 11a (48 mg) as an off-white solid. Yield 58 % (48 mg); mp 244-
246 °C; [α]D25 +37.9 (c 0.463, DMF). IR (ATR) ν = 3397, 3361, 3232, 3136, 2981, 2923, 2852, 
1775, 1649, 1514, 1415, 1322, 1260, 1175, 1110, 917, 831, 759, 702 cm-1. 1H NMR (400 MHz, 
DMSO-d6) δ 1.36-1.37 (m, 6H, CH(CH3)2), 1.49 (d, 3H, 3J = 6.8 Hz, CH3), 2.24 (s, 3H, Pyrr-
CH3), 4.86 (spt, 1H, 3J = 6.0 Hz, CH(CH3)2), 5.11 (quint, 1H, 3J = 7.2 Hz, Hz, CONHCH), 7.55-
7.61 (m, 2H, 2 × Ar-H), 8.47 (d, 1H, 3J = 8.4 Hz, Ar-H-5), 8.88 (d, 1H, 3J = 7.6 Hz, CONHCH), 
9.26 (s, 1H, CONHAr), 12.27 (br s, 1H, oxadiazolone-NH/Pyrr-NH), 12.45 (s, 1H, oxadiazolone-
NH/Pyrr-NH). 13C NMR (100 MHz, DMSO-d6) δ 10.76 (Pyrr-CH3), 16.87 (CH3), 21.77 
(CH(CH3)2), 21.80 (CH(CH3)2), 41.73 (CH), 71.36 (CH(CH3)2), 108.60, 109.74, 111.65, 117.99, 
118.63, 120.55, 128.28, 129.82, 131.35, 145.20, 154.89, 156.22, 157.23, 165.10 (Ar-CONH). MS 
(ESI) m/z = 480.1 ([M-H]-). HRMS for C20H20Cl2N5O5: calculated 480.0841, found 480.0848. 
HPLC: tr 12.275 min (95.2 % at 220 nm, method A). 
(S)-2-(2-(3,4-Dichloro-5-methyl-1H-pyrrole-2-carboxamido)-5-((1-(5-oxo-4,5-dihydro-
1,3,4-oxadiazol-2-yl)ethyl)carbamoyl)phenoxy)ethan-1-aminium chloride (12). Synthesized 
according to General procedure H with stirring the reaction mixture for 5 hours. The product was 
additionally purified with reverse-phase flash chromatography on a Biotage Isolera One System 
using a Biotage SNAP Cartridge KP-C18-HS 12 g column and 15-60% acetonitrile in TFA (0.1 
%) as a mobile phase to afford 12 (5  mg) as an off white solid. Yield 16 % (5 mg); mp 234-236 
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°C; [α]D25 +29.6 (c 0.180, MeOH). 1H NMR (400 MHz, DMSO-d6) δ 1.50 (d, 3H, 3J = 7.6 Hz, 
CH3), 2.25 (s, 3H, Pyrr-CH3), 3.34 (2H, OCH2CH2NH3+, overlapping with the signal for water), 
4.39 (t, 2H, 3J = 4.4 Hz, OCH2CH2NH3+), 5.11 (quint, 1H, 3J = 7.2 Hz, CONHCH), 7.61-7.62 (m, 
2H, Ar-H-4,6), 8.24 (s, 3H, NH3+), 8.41 (d, 1H, 3J = 8.8 Hz, Ar-H-3), 8.98 (d, 1H, 3J = 7.6 Hz, 
CONHCH), 9.26 (s, 1H, CONHAr), 12.31 (s, 1H, oxadiazole-NH/Pyrr-NH), 12.51 (s, 1H, 
oxadiazole-NH/Pyrr-NH). MS (ESI) m/z = 484.1 ([M-H]+). HRMS for C19H20Cl2N5O6: calculated 
484.0791, found 484.0798. HPLC: tr 3.697 (97.8 % pri 280 nm, method A). 
3-Isopropoxy-4-nitro-N-(pyridin-2-ylmethyl)benzamide (13a). Synthesized according to 
General procedure D with pyridin-2-ylmethanamine (420 µL, 3.73 mmol) as a reagent. The crude 
product was purified with flash column chromatography using dichloromethane/methanol (20/1) 
as an eluent to give 13a (612 mg) as pale yellow solid. Yield 66% (612 mg); mp 73-75 °C. IR 
(ATR) ν = 3192, 2991, 2937, 1656, 1517, 1412, 1357, 1301, 1253, 1103, 1008, 960, 837, 751 cm-
1
. 
1H NMR (400 MHz, CDCl3) δ 1.44 (d, 6H, 3J = 6.4 Hz, CH(CH3)2), 4.78 (d, 2H, 3J = 4.4 Hz, 
CH2), 4.82 (spt, 1H, 3J = 6.4 Hz, CH(CH3)2), 7.26-7.27 (m, 1H, NH/Ar-H-2), 7.29-7.30 (m, 1H, 
NH/Ar-H-2), 7.35 (d, 1H, 3J = 8.0 Hz, Ar-H-5), 7.40 (dd, 1H, 3J = 8.4 Hz, 4J = 1.6 Hz, Ar-H-6), 
7.70-7.84 (m, 4H, 4 × Pyridine-H), 8.59-8.61 (d, 1H, NH). 13C NMR (100 MHz, DMSO-d6) δ 
21.58 (CH(CH3)2), 44.86 (CH2), 72.38 (CH(CH3)2), 114.91, 119.40, 121.12, 122.21, 124.76, 
136.78, 138.76, 142.15, 148.91, 149.76, 158.28, 164.60 (CONH). MS (ESI) m/z = 314.38 ([M-
H]-). 
4-Amino-3-isopropoxy-N-(pyridin-2-ylmethyl)benzamide (14a). Synthesized according to 
General procedure E with stirring the reaction mixture for 4 hours. Yellow oil; yield 99% (230 
mg). IR (ATR) ν = 3464, 3289, 3170, 2978, 1622, 1546, 1506, 1303, 1225, 1110, 956, 825, 754, 
608 cm-1. 1H NMR (400 MHz, DMSO-d6) δ 1.29 (d, 6H, 3J = 6.0 Hz, CH(CH3)2), 4.52 (d, 2H, 3J 
= 6 Hz, CH2), 4.56 (spt, 1H, 3J = 6Hz, CH(CH3)2), 5.22 (s, 2H, NH2), 6.64 (d, 1H, 3J = 8.0 Hz, 
Ar-H-5), 7.24-7.29 (m, 2H, 2 × Pyridine-H), 7.35 (dd, 1H, 3J = 8.0 Hz, 4J = 2.0 Hz, Ar-H-6), 7.40 
(d, 1H, 4J = 2.0 Hz, Ar-H-2), 7.73-7.77 (td, 1H, Pyridine-H), 8.49-8.51 (dq, 1H, Pyridine-H), 
8.72 (t, 1H, 3J = 6.0 Hz, NH). 13C NMR (100 MHz, DMSO-d6) δ 21.96 (CH(CH3)2), 44.57 (CH2), 
70.28 (CH(CH3)2), 112.55, 112.91, 120.83, 121.24, 121.33, 121.91, 136.61, 142.39, 143.09, 
148.70, 159.43, 166.27 (CONH). MS (ESI) m/z = 284.39 ([M-H]-). 
4,5-Dibromo-N-(2-isopropoxy-4-((pyridin-2-ylmethyl)carbamoyl)phenyl)-1H-pyrrole-2-
carboxamide (15a). Synthesized according to General procedure F but a few seconds after the 
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addition of pyridine a precipitate started to form which was filtered off and washed with 
methanol (10 mL) to give 15a (37 mg) as white solid. Yield 13% (37 mg); mp 253-255 °C. IR 
(ATR) ν = 3383, 2976, 2633, 1652, 1521, 1402, 1310, 1274, 1201, 1127, 967, 874, 753 cm-1. 1H 
NMR (400 MHz, DMSO-d6) δ 1.34 (d, 6H, 3J = 6.0 Hz, CH(CH3)2), 4.62 (d, 2H, 3J = 5.6 Hz, 
CH2), 4.71 (spt, 1H, 3J = 6.0 Hz, CH(CH3)2), 7.18 (d, 1H, 4J = 2.4 Hz, Pyrr-CH), 7.36-7.39 (m, 
1H, Pyridine-H), 7.43 (d, 1H, 3J = 7.6 Hz, Pyridine-H), 7.56 (dd, 1H, 3J = 8.0 Hz, 4J = 1.6 Hz, 
Ar-H-6), 7.62 (d, 1H, 4J = 1.6 Hz, Ar-H-2), 7.86-7.90 (td, 1H, Pyridine-H), 7.94 (d, 1H, 3J = 8.0 
Hz, Ar-H-5), 8.57-8.58 (m, 1H, Pyridine-H), 9.05 (s, 1H, CONHAr), 9.16 (t, 1H, 3J = 5.6 Hz, 
CONHCH2), 13.03 (d, 1H, 4J = 2.0 Hz, Pyrr-NH). 13C NMR (100 MHz, DMSO-d6) δ 21.75 
(CH(CH3)2), 44.72 (CH2), 71.29 (CH(CH3)2), 98.43, 106.30, 112.77, 113.83, 119.75, 120.96, 
122.08, 122.60, 127.60, 130.39, 130.51, 136.72, 148.31, 148.82, 157.02, 158.84, 165.68 (Ar-
CONH). MS (ESI) m/z = 533.0 ([M-H]-), HRMS for C21H19Br2N4O3: calculated 532.9824, found 
532.9834. HPLC: tr 8.831 min (98.9% at 280 nm, method A). 
Methyl 2-hydroxy-4-nitrobenzoate (17). Synthesized according to General procedure A without 
purification with petroleum ether. The starting compound (16, 5.00 g, 25.7 mmol) was dissolved 
from the begining. Yellow solid; yield 89% (4.80 g); mp 97-99 °C (101-102 °C, lit.[42]). IR 
(ATR) ν = 3114, 2961, 2868, 1676, 1519, 1434, 1339, 1250, 1197, 1070, 957, 902, 812, 786, 732 
cm-1. 1H NMR (400 MHz, CDCl3) δ 4.05 (s, 3H, COOCH3), 7.73 (dd, 1H, 3J = 8.8 Hz, 4J = 2.4 
Hz, Ar-H-5), 7.85 (d, 1H, 4J = 2.4 Hz, Ar-H-3), 8.05 (d, 1H, 3J = 8.4 Hz, Ar-H-6), 11.01 (s, 1H, 
OH). 
Methyl 2-(benzyloxy)-4-nitrobenzoate (18a) [43]. To a solution of methyl 2-hydroxy-4-
nitrobenzoate (17, 1.00 g, 5.06 mmol) and potassium carbonate (1.40 g, 10.1 mmol) in 
acetonitrile (40 mL) benzyl bromide (0.60 mL, 5.06 mmol) was added and the reaction mixture 
was stirred at 60 °C for 15 h. The solvent was evaporated under reduced pressure, the residue was 
dissolved in ethyl acetate (40 mL) and water (40 mL), the organic phase was washed with brine 
(2 × 30 mL), dried over Na2SO4, filtered and the solvent removed under reduced pressure to give 
18a (1.24 g) as yellow solid. Yield 85% (1.24 g); mp 74-76 °C; 1H NMR (400 MHz, CDCl3) δ 
3.97 (s, 3H, COOCH3), 5.30 (s, 2H, CH2), 7.35-7.54 (m, 5H, 5 × Ar-H), 7.86-7.96 (m, 2H, 3 × 
Ar-H). 
2-(Benzyloxy)-4-nitrobenzoic acid (19a) [43]. Synthesized according to General procedure C. 
Yellow solid; yield 87% (1.02 g); mp 151-153 °C. IR (ATR) ν = 3061, 2941, 2865, 2648, 2537, 
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1678, 1522, 1345, 1244, 1082, 988, 949, 875, 811, 734 cm-1. 1H NMR (400 MHz, CDCl3) δ 5.42 
(s, 2H, CH2), 7.45-7.52 (m, 5H, 5 × Ar-H’), 8.00 (dd, 1H, 3J = 8.4 Hz, 4J = 2.0 Hz, Ar-H-5), 8.03 
(d, 1H, 4J = 2.0 Hz, Ar-H-3), 8.38 (d, 1H, 3J = 8.4 Hz, Ar-H-6), 10.56 (br s, 1H, COOH). 
Methyl (2-(benzyloxy)-4-nitrobenzoyl)glycinate (20a). Synthesized according to General 
procedure D with 2-(benzyloxy)-4-nitrobenzoic acid (19a, 1.00 g, 3.64 mmol) and glycine methyl 
ester hydrochloride (505 mg, 4.03 mmol) as reagents. The crude product was purified by adding 
petroleum ether, the obtained suspension was sonicated, filtered and washed with petroleum ether 
to give 20a (1.18 g) as yellow solid. Yield 85% (1.18 g); mp 119-122 °C. IR (ATR) ν = 3367, 
3105, 2950, 2855, 1750, 1648, 1518, 1442, 1342, 1202, 1101, 989, 923, 838, 743 cm-1. 1H NMR 
(400 MHz, DMSO-d6) δ 3.66 (s, 1H, COOCH3), 4.08 (d, 2H, 3J = 6.0 Hz, CONHCH2), 5.44 (s, 
2H, OCH2Ph), 7.32-7.54 (m, 5H, 5 × Ar-H’), 7.85 (d, 1H, 3J = 8.4 Hz, Ar-H-6), 7.91 (dd, 1H, 3J 
= 8.4 Hz, 4J = 2.0 Hz, Ar-H-5), 7.98 (d, 1H, 4J = 2.0 Hz, Ar-H-3), 8.90 (t, 1H, 3J = 6.0 Hz, 
CONHCH2). 13C NMR (100 MHz, DMSO-d6) δ 41.25 (CH2), 51.81 (COOCH3), 70.35 (CH2), 
108.46, 115.68, 127.33, 128.01, 128.52, 130.03, 131.09, 135.90, 149.35, 155.98, 164.44 
(CONH), 169.93 (COOCH3). MS (ESI) m/z = 367.32 ([M+Na]+). 
Methyl (4-amino-2-(benzyloxy)benzoyl)glycinate (21a). A mixture of compound 20a (675 
mg, 1.98 mmol) and SnCl2 (1.85 g, 16.9 mmol) in ethyl acetate (20 mL) and methanol (20 mL) 
was stirred at 55 °C for 15 h. The solvent was removed under reduced pressure and the residue 
dissolved in ethyl acetate (20 mL) and water (20 mL). The aqueous phase was basified with 1 M 
NaOH to pH 9 and extracted with ethyl acetate (2 × 20 mL). The combined organic phases were 
dried over Na2SO4, filtered and the solvent evaporated under reduced pressure. The crude product 
was purified with flash column chromatography using ethyl acetate/petroleum ether (2/1) as an 
eluent to give compound 21a (356 mg) as yellow oil. Yield 58% (356 mg). IR (ATR) ν = 3378, 
3335, 3232, 2953, 1737, 1596, 1539, 1440, 1281, 1198, 1118, 1005, 825, 732 cm-1. 1H NMR 
(400 MHz, CDCl3) δ 3.70 (s, 1H, COOCH3), 4.16 (d, 2H, 3J = 5.6 Hz, CONHCH2), 4.33 (br s, 
2H, NH2), 5.17 (s, 2H, CH2Ph), 6.31 (d, 1H, 4J = 2.0 Hz, Ar-H-3), 6.38 (dd, 1H, 3J = 8.4 Hz, 4J = 
2.0 Hz, Ar-H-5), 7.35-7.48 (m, 5H, 5 × Ar-H’), 8.04 (d, 1H, 3J = 8.8 Hz, Ar-H-6), 8.29 (t, 1H, 3J 
= 4.4 Hz, CONHCH2). 13C NMR (100 MHz, DMSO-d6) δ 41.20 (CH2), 51.64 (COOCH3), 69.39 
(CH2), 97.31, 106.47, 108.42, 127.34, 127.88, 128.51, 132.73, 136.61, 153.44, 158.06, 165.05 
(CONH), 170.69 (COOCH3). MS (ESI) m/z = 337.33 ([M+Na]+). 
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Methyl (2-(benzyloxy)-4-(4,5-dibromo-1H-pyrrole-2-carboxamido)benzoyl)glycinate 
(22a). Synthesized according to General procedure F. The crude product was purified by adding 
diethyl ether (15 mL) and methanol (5 mL), the obtained suspension was sonicated, filtered and 
washed with diethyl ether (2 × 10 mL) to obtain 22a (192 mg) as white solid. Yield 34% (192 
mg); mp 103-106 °C. IR (ATR) ν = 3421, 3370, 3306, 3129, 1736, 1627, 1593, 1520, 1332, 
1217, 1076, 979, 836, 740 cm-1. 1H NMR (400 MHz, DMSO-d6) δ 3.65 (s, 3H, COOCH3), 4.08 
(d, 2H, 3J = 6.0 Hz, CONHCH2), 5.34 (s, 2H, OCH2Ph), 7.27 (d, 1H, 4J = 2.8 Hz, Pyrr-CH), 7.32-
7.42 (m, 4H, 4 × Ar-H), 7.52-7.54 (m, 2H, 2 × Ar-H), 7.77-7.86 (m, 2H, 2 × Ar-H), 8.58 (t, 1H, 
3J = 6.0 Hz, CONHCH2), 10.05 (s, 1H, Pyrr-CONH-Ar), 13.01 (d, 1H, 4J = 2.4 Hz, Pyrr-NH); 
13C NMR (100 MHz, DMSO-d6) δ 41.26 (CH2), 51.65 (COOCH3), 69.74 (CH2), 98.19, 104.16, 
106.53, 111.74, 114.17, 116.57, 127.34, 127.46, 127.90, 128.44, 131.58, 136.14, 142.86, 156.49, 
157.39, 164.48 (Ar-CONH), 170.29 (COOCH3). MS (ESI) m/z = 562.0 ([M-H]-), HRMS for 
C22H18Br2N3O5: calculated 561.9613, found 561.9606. HPLC: tr 12.252 min (95.1% at 280 nm, 
method A). 
(2-(Benzyloxy)-4-(4,5-dibromo-1H-pyrrole-2-carboxamido)benzoyl)glycine (23a). 
Synthesized according to General procedure G with 2 equivalents of 1M NaOH (140 µL, 140 
µmol). White solid; yield 46% (18 mg); mp 195-198 °C. IR (ATR) ν = 3369, 3222, 2930, 1714, 
1618, 1510, 1408, 1294, 1205, 1119, 1019, 842, 737 cm-1. 1H NMR (400 MHz, DMSO-d6) δ 4.00 
(d, 2H, 3J = 5.6 Hz, CONHCH2), 5.33  (s, 2H, CH2Ph), 7.26 (s, 1H, Pyrr-CH), 7.30-7.55 (m, 6H, 
5 × Ar-H’, Ar-H-5), 7.77 (d, 1H, 4J = 2.0 Hz, Ar-H-3), 7.87 (d, 1H, 3J = 8.4 Hz, Ar-H-6), 8.49 (t, 
1H, 3J = 5.6 Hz, CONHCH2), 10.03 (s, 1H, Pyrr-CONH-Ar), 12.68 (br s, 1H, COOH/Pyrr-NH), 
13.00 (br s, 1H, COOH/Pyrr-NH); 13C NMR (100 MHz, DMSO-d6) δ 41.32 (CH2), 69.84 (CH2), 
98.18, 104.16, 106.53, 111.75, 114.17, 116.62, 127.44, 127.48, 127.93, 128.43, 131.63, 136.07, 
142.82, 156.51, 157.40, 164.23 (Ar-CONH), 171.21 (COOH). MS (ESI) m/z = 547.9 ([M-H]-), 
HRMS for C21H16Br2N3O5: calculated 547.9457, found 547.9454. HPLC: tr 10.497 min (97.5% at 
280 nm, method A). 
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 1 
HIGHLIGHTS 
 
- An optimized series of N-phenylpyrrolamide DNA gyrase B inhibitors was prepared. 
- Low nanomolar IC50 values against DNA gyrase were obtained. 
- Compound 12 had an IC50 value of 13 nM against E. coli DNA gyrase. 
- MIC values of 11a were 1.56 µM against E. faecalis and 3.13 µM against S. aureus. 
- Compound 11a inhibited MRSA and VRE with MIC values of 3.13 µM. 
